Dub3 expression correlates with tumor progression and poor prognosis in human epithelial ovarian cancer

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Bo ZhouJing Liu

Abstract

Dub3 is a deubiquitinating enzyme. It is highly expressed in tumor-derived cell lines and has an established role in tumor proliferation. However, the role of Dub3 in human ovarian cancer remains unclear. Expression of Dub3 was evaluated in ovarian cancer tissues and cell lines by immunohistochemistry and Western blot analysis. The relationship between Dub3 expression and clinicopathological characteristics was analyzed. Using RNA interference, the effects of Dub3 on cell proliferation and apoptosis were investigated in ovarian cancer cell line. All normal ovary tissues exhibited very little or no Dub3 immunoreactivity. High levels of Dub3 expression were examined by immunohistochemical analysis in 13.3% of cystadenomas, in 30.0% of borderline tumors, and in 58.9% of ovarian carcinomas, respectively. Dub3 expression was significantly associated with lymph node metastasis and clinical staging (P<0.05). Multivariate survival analysis indicated that Dub3 expression was an independent prognostic indicator of the survival of patients with ovarian cancer. Furthermore, the expression of Cdc25A was closely correlated with that of Dub3 in cancer cells and tissues. Knockdown of Dub3 could inhibit the proliferation of ovarian cancer cells...Continue Reading

References

Jan 19, 2000·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·S G Silverberg
Sep 21, 2000·The Journal of Clinical Investigation·M G CangiM Loda
Nov 8, 2001·Current Opinion in Cell Biology·J Bartek, J Lukas
Dec 12, 2003·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Jeffrey D SeidmanBrigitte M Ronnett
Dec 31, 2003·The Journal of Biological Chemistry·James F BurrowsJames A Johnston
Dec 6, 2005·Cell·Sebastian M B NijmanRené Bernards
Feb 7, 2007·Cancer Research·Dipankar RayHiroaki Kiyokawa
Jun 15, 2007·Nature Reviews. Cancer·Rose BoutrosBernard Ducommun
Nov 6, 2007·Current Biology : CB·Francesco NicassioElisabetta Citterio
Feb 4, 2009·The Journal of Biological Chemistry·James F BurrowsJames A Johnston
Feb 12, 2010·The Journal of Biological Chemistry·Michelle de la VegaJames A Johnston
Mar 17, 2010·Nature Cell Biology·Yaron PeregVishva M Dixit
Oct 27, 2010·FEBS Letters·Boyko S AtanassovSharon Y Dent
Mar 31, 2011·Nature Communications·Michelle de la VegaJames A Johnston
Feb 6, 2013·Nature Reviews. Clinical Oncology·Robert L ColemanThomas J Herzog
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Mar 12, 2019·Nucleic Acids Research·Charles DuckerPeter E Shaw
Nov 9, 2019·Molecular Genetics & Genomic Medicine·Xiao-Dan LinXue-Yi Xue
Feb 20, 2019·Cell Death and Differentiation·Qi ZhangXiao-Dong Zhang
Nov 10, 2018·Cell Communication and Signaling : CCS·Aidan P McCannJames F Burrows
Aug 27, 2019·Biochimica Et Biophysica Acta. Reviews on Cancer·Ji ChengWenyi Wei
Nov 24, 2020·The International Journal of Biochemistry & Cell Biology·Charles Ducker, Peter E Shaw
Aug 30, 2021·Cancer Cell International·Guang-Fei YangYan-Yang Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis